Amid market volatility, Novartis and Shopify offer a powerful combination of defensive stability and high-growth potential. Novartis’s proven ability to navigate patent cliffs and sustain dividends, coupled with Shopify’s dominance in a vast e-commerce market, positions both as foundational holdings for a long-term portfolio.
The core principle of long-term investing is simple: identify exceptional companies, purchase their shares, and allow the power of compounding to work over years, or even decades. The challenge, however, lies in the initial selection. Not every company possesses the durable competitive advantages, financial resilience, and growth runway necessary to deliver outsized returns over the long haul.
Two names that consistently meet these rigorous criteria are Novartis AG and Shopify Inc.. One is a pharmaceutical titan with a century of history, the other a dynamic disruptor shaping the future of commerce. Together, they represent a compelling dual strategy for investors seeking both stability and explosive growth.
Novartis: The Blue-Chip Pharmaceutical Powerhouse
Novartis stands as a paragon of stability and innovation in the global healthcare sector. The company’s investment thesis is built on a multi-pronged strategy that effectively mitigates risk while driving consistent financial performance.
Its most significant strength is a deep and diversified product portfolio. As of its latest earnings report, the company boasted ten blockbuster drugs each generating over $1 billion in sales. This diversification is crucial. It insulates the company from the inherent volatility of the pharmaceutical industry, where a single drug’s failure or a patent expiration can cripple less-prepared firms.
This leads directly to Novartis’s most impressive recent feat: successfully navigating a major patent cliff. The loss of exclusivity for Entresto, a cornerstone heart failure medication, posed a substantial threat. Yet, the company’s Q3 2025 results demonstrated remarkable resilience. Revenue grew 8% year-over-year to $13.9 billion, while earnings per share increased 9% to $2.25. This performance, achieved amidst generic competition, is a testament to the strength of its broader portfolio and its strategic focus on innovation.
The engine behind this success is a robust and innovative pipeline. The recent U.S. approval of Fabhalta for paroxysmal nocturnal hemoglobinuria in December 2023 is a prime example of Novartis’s ability to replenish its lineup with new, high-potential therapies. This constant cycle of innovation—launching new drugs and securing label expansions for existing ones—ensures the company can continually overcome the patent expirations that are an inevitable part of the industry.
For income-focused investors, Novartis is equally compelling. The company has increased its dividend payout for 28 consecutive years, a streak that underscores its consistent profitability and shareholder-friendly capital allocation. Its current forward yield of 3% significantly outpaces the S&P 500 average of 1.2%, offering a attractive source of passive income that grows over time.
Shopify: The Architect of the Future of E-Commerce
While Novartis offers defensive stability, Shopify provides pure, unadulterated growth potential. The company’s ambition is not merely to be a successful tech firm but to build what management calls a “100-year company.” Its progress toward that goal has been nothing short of spectacular.
Shopify’s core business is providing the essential infrastructure for commerce. Its platform empowers businesses, from nascent entrepreneurs to massive global brands, to launch, grow, and manage their online stores with unparalleled ease. The value proposition is powerful: a suite of customizable templates, a vast app store, and integrated tools for marketing, analytics, inventory, and shipping management.
This has translated into dominant market leadership. Shopify captured an estimated 12% of the U.S. e-commerce platform market by the end of 2024, a figure that grew from 10% just a year prior. This growth is occurring in a sector with immense white space; global e-commerce penetration is still climbing, and Shopify is positioned to capture a disproportionate share of that expansion.
Perhaps the most underappreciated aspect of Shopify’s business is its powerful economic moat, built on high switching costs. Merchants invest significant time, money, and brand identity into building their Shopify storefronts. Migrating to a competitor is not a simple task; it is a complex, costly, and risky endeavor that most businesses will undertake only under extreme duress. This lock-in effect creates a recurring revenue stream and provides incredible stability for a growth company.
A long-standing critique of Shopify was its lack of profitability. However, the company has decisively silenced those concerns. By divesting its capital-intensive logistics business and sharpening its operational focus, Shopify has achieved profitability in three of the last four quarters. This trend toward sustained earnings and expanding margins marks a critical maturation point, transforming the company from a speculative growth story into a profitable growth engine.
Why These Stocks Belong in a Long-Term Portfolio
The combination of Novartis and Shopify provides investors with a balanced, complementary approach to wealth building.
- Novartis offers downside protection through its essential healthcare products, proven ability to manage industry-specific risks, and reliable dividend. It is a bedrock holding that will perform consistently across economic cycles.
- Shopify offers massive upside potential through its leadership in the high-growth e-commerce sector, its formidable competitive moat, and its recent transition to profitability. It is the engine for portfolio appreciation.
Together, they represent a classic barbell strategy: one end anchored in stability and income, the other leveraged for high growth. This diversification across sectors and investment styles is a cornerstone of prudent long-term portfolio construction.
The Investor Takeaway
Identifying companies that can not only survive but thrive over multiple decades is the ultimate goal of long-term investing. Both Novartis and Shopify have demonstrably passed this test. Novartis has weathered patent expirations and economic downturns while continuing to innovate and reward shareholders. Shopify has carved out a dominant, defensible position in a future-proof industry and has now reached the critical inflection point of sustained profitability.
For investors looking beyond short-term market noise to build genuine, lasting wealth, these two companies provide a compelling foundation. Their distinct strengths address different investor needs, but their shared qualities—competitive moats, excellent leadership, and clear growth trajectories—make them elite candidates for any buy-and-hold portfolio.
For the fastest, most authoritative analysis of breaking financial news and deep dives on the stocks that matter, make onlytrustedinfo.com your primary destination. We cut through the noise to deliver the insights you need to invest with confidence.
